Q 32 Bio Inc (QTTB)

01:06 AM

Q32 Bio Inc. (NASDAQ:QTTB) Receives $24.71 Average Target Price from Brokerages - Defense World

01:06 AM

Mar 31, 2025

Layoff Tracker: Arbutus Cuts 57% of Workforce - BioSpace

Mar 31, 2025

Mar 28, 2025

QTTB stock touches 52-week low at $1.79 amid market challenges - Investing.com India

Mar 28, 2025

Mar 21, 2025

Fierce Biotech Layoff Tracker 2025: Elevation eliminates 70% of staff; Vaxart trims team - Fierce Biotech

Mar 21, 2025

Mar 20, 2025

Oppenheimer maintains Q32 Bio at Outperform, $20 target - Investing.com

Mar 20, 2025

Mar 20, 2025

Oppenheimer maintains Q32 Bio at Outperform, $20 target By Investing.com - Investing.com UK

Mar 20, 2025

Mar 14, 2025

Wells Fargo & Company Lowers Q32 Bio (NASDAQ:QTTB) Price Target to $15.00 - Defense World

Mar 14, 2025

Mar 12, 2025

Q32 Bio price target lowered to $15 from $16 at Wells Fargo - TipRanks

Mar 12, 2025

Mar 12, 2025

Q32 Bio Inc’s Intellectual Property Challenges: Navigating Risks and Competitive Pressures - TipRanks

Mar 12, 2025

Mar 12, 2025

Q32 Bio Reports Promising Trial Results and Financials - TipRanks

Mar 12, 2025

Mar 11, 2025

Q32 Bio: Q4 Earnings Snapshot - Midland Daily News

Mar 11, 2025

Mar 11, 2025

Q32 Bio Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 11, 2025

Mar 11, 2025

Q32 Bio Inc. SEC 10-K Report - TradingView

Mar 11, 2025

Mar 11, 2025

Q32 Bio: Q4 Earnings Snapshot -March 11, 2025 at 07:21 am EDT - Marketscreener.com

Mar 11, 2025

Mar 11, 2025

Q32 Bio's Breakthrough: Alopecia Drug Success Backed by $78M War Chest - StockTitan

Mar 11, 2025

Mar 10, 2025

Q32 Bio Inc. (NASDAQ:QTTB) Shares Purchased by Rhumbline Advisers - Defense World

Mar 10, 2025

Mar 09, 2025

Q32 Bio presents results from SIGNAL-AA Part 2a trial of bempikibart - TipRanks

Mar 09, 2025

Mar 09, 2025

Q32 Bio (QTTB) Projected to Post Earnings on Tuesday - Defense World

Mar 09, 2025

Mar 08, 2025

Can This New Alopecia Drug Maintain Hair Growth After Treatment Stops? Q32 Bio's Trial Reveals Surprising Results - StockTitan

Mar 08, 2025

Mar 08, 2025

Q32 Bio Inc. (NASDAQ:QTTB) Receives $24.86 Average PT from Brokerages - Defense World

Mar 08, 2025

Mar 07, 2025

Q32 Bio Inc expected to post a loss of $1.51 a shareEarnings Preview - TradingView

Mar 07, 2025

Mar 02, 2025

Reviewing Q32 Bio (NASDAQ:QTTB) & Ardelyx (NASDAQ:ARDX) - Defense World

Mar 02, 2025

Feb 28, 2025

Finance Watch: BridgeBio’s Oncology Spinout Reveals Go-Public Plan - Citeline News & Insights

Feb 28, 2025

Feb 28, 2025

Q32 Bio Announces Late-Breaking Presentation of Results from SIGNAL-AA Part A Clinical Trial of Bempikibart in Alopecia Areata at the 2025 American Academy of Dermatology Annual Meeting - Longview News-Journal

Feb 28, 2025

Feb 28, 2025

Can This New Antibody Treatment Finally Solve Severe Alopecia Areata? AAD Meeting Will Reveal Key Data - Stock Titan

Feb 28, 2025

Feb 27, 2025

QTTB stock touches 52-week low at $2.27 amid market challenges - Investing.com Australia

Feb 27, 2025

Feb 27, 2025

QTTB stock touches 52-week low at $2.27 amid market challenges By Investing.com - Investing.com South Africa

Feb 27, 2025

Feb 26, 2025

Q32 Bio to Participate in Upcoming March Investor Conferences - PR Newswire

Feb 26, 2025

Feb 24, 2025

IPOs Numbers Rise In 2024 But Dwindling Returns Could Diminish Potential In 2025 - Citeline News & Insights

Feb 24, 2025

Feb 21, 2025

Savant Capital LLC Makes New $53,000 Investment in Q32 Bio Inc. (NASDAQ:QTTB) - Defense World

Feb 21, 2025

Feb 20, 2025

QTTB stock touches 52-week low at $2.44 amid market challenges - Investing.com India

Feb 20, 2025

Feb 15, 2025

Piper Sandler cuts Q32 Bio stock rating to neutral, slashes target - MSN

Feb 15, 2025

Feb 14, 2025

What is Leerink Partnrs’ Forecast for Q32 Bio Q1 Earnings? - Defense World

Feb 14, 2025

Feb 13, 2025

Petri Dish: a new AbbVie deal, layoffs, and CFO departures - The Business Journals

Feb 13, 2025

Feb 13, 2025

Bleakley Financial Group LLC Invests $149,000 in Q32 Bio Inc. (NASDAQ:QTTB) - Defense World

Feb 13, 2025

Feb 13, 2025

Q32 Bio refocuses on alopecia treatment, ends renal trial - MSN

Feb 13, 2025

Feb 13, 2025

BMO cuts Q32 Bio stock rating, slashes price target to $3 - MSN

Feb 13, 2025

Feb 12, 2025

BMO Capital Downgrades Q32 Bio (LSE:0T6G) - Nasdaq

Feb 12, 2025

Feb 12, 2025

Q32 Bio (NASDAQ:QTTB) Lowered to “Market Perform” Rating by BMO Capital Markets - Defense World

Feb 12, 2025

Feb 12, 2025

Finance Watch: Third Harmonic, Q32 Bio Cut Jobs To Focus On Lead Assets - insights.citeline.com

Feb 12, 2025